Achieve Compliance with the New FDA QMSR Without Slowing Down Your Business
At FDAmedix, we help small and mid-sized medical-device and IVD companies implement or upgrade a robust, inspection-ready QMS — from gap analysis to mock audits — so you avoid regulatory setbacks, speed up time to market, and build operational confidence.
Request Free QMSR Compliance Consultation
FDAmedix: Your Partner for QMSR Compliance Success
FDAmedix specializes in helping small and mid-size medical device and IVD/IVDR manufacturers meet the evolving expectations of the FDA. With deep expertise in the new Quality Management System Regulation (QMSR), our team supports companies that need to build QMSR-aligned processes from the ground up or strengthen their existing compliance programs. Changes made to QSR subparts by QMSR are illustrated in the images on this page. Whether you’re preparing for regulatory scrutiny or entering the U.S. market, FDAmedix provides the guidance you need to do it with confidence.
The New QMSR: What Every Manufacturer Needs to Know
The FDA’s introduction of the QMSR on February 2, 2024 represents the most significant update to 21 CFR Part 820 in decades. By incorporating ISO 13485:2016, the QMSR harmonizes U.S. expectations with international standards—reducing redundancy, clarifying requirements, and streamlining global compliance. Manufacturers operating in the U.S. must understand how these changes impact product development, manufacturing, documentation, and inspection readiness.
A Modernized Framework Built for Global Alignment
Under the QMSR, manufacturers benefit from a clean, modern regulatory structure that reflects the language and approach of ISO 13485:2016 and ISO 9000:2015. But this alignment does not eliminate FDA-specific obligations. The QMSR adds critical requirements around FDA risk expectations, electronic records and signatures, and documentation practices. Understanding these nuances is essential—and FDAmedix helps you navigate them with clarity and efficiency.
Transition Timeline and Inspection Expectations
The FDA has established a two-year transition period, with full QMSR implementation taking effect on February 2, 2026. While the structure of the regulation is changing, the FDA’s inspection authority remains firmly in place. ISO 13485 certification alone will not satisfy FDA requirements. For ISO-aligned companies, the transition may be smooth—but for manufacturers operating only under legacy Part 820, significant updates may be required. FDAmedix ensures you’re not only compliant but fully inspection-ready.
Expert QMSR Transition Support from FDAmedix
FDAmedix delivers comprehensive QMSR gap analyses, pinpointing exactly where your current practices diverge from FDA expectations. We then build customized transition plans that help your organization adopt the QMSR efficiently and effectively. Our experts prioritize high-risk gaps, guide regulatory-critical decisions, and help you implement changes that withstand inspection scrutiny—saving you time, cost, and compliance risk.
Full-Spectrum Compliance Services to Strengthen Your Organization
Beyond transition planning, FDAmedix offers a suite of services designed to elevate your compliance and operational resilience. Our audits and mock FDA inspections prepare your team for real-world regulatory interactions. We strengthen risk management programs to meet QMSR expectations and assess suppliers to ensure your entire supply chain supports compliance. With FDAmedix, you gain a dedicated partner focused on reducing risk and enhancing regulatory confidence across your organization.